SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on October 10, 2002; DOI 10.1182/blood-2002-05-1474. This Article Full Text (PDF) All Versions of this Article: 2002-05-1474v1 101/4/1277    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Roumier, C. Articles by Preudhomme, C. Search for Related Content PubMed PubMed Citation Articles by Roumier, C. Articles by Preudhomme, C. Social Bookmarking                   What's this? Submitted May 22, 2002 Accepted September 6, 2002 Mo AML, clinical and biological features of the disease including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH) Christophe Roumier, Virginie Eclache, Michelle Imbert, Frederic Davi, Elizabeth Macintyre, Richard Garand, Pascaline Talmant, Pascale LePelley, Jean-Luc Lai, Olivier Casasnovas, Marc Maynadie, Francine Mugneret, Christele Bilhou-Naberra, Francoise Valensi, Isabelle Radford, Marie-Joelle Mozziconacci, Christine Arnoulet, Elianne Duchayne, Nicole Dastugue, Pascale Cornillet, Sylvie Daliphard, Francine Garnache, Najiba Boudjerra, Helene Jouault, Odile Fenneteau, Beatrice Pedron, Roland Berger, Georges Flandrin, Pierre Fenaux, and Claude Preudhomme* Laboratoire d'Hematologie A, CHU Lille, Lille, France Unite INSERM 524, Institut de Recherche sur le Cancer de Lille, Lille, France Laboratoire d Hematologie, Hopital Jean Verdier, Bondy, Assistance Publique Hopitaux de Paris, Paris, France Hematologie Biologique, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Paris, France Hematologie Biologique, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France Hematologie Biologique, Hopital Necker, Assistance Publique Hopitaux de Paris, Paris, France Laboratoire d Hematologie, Institut de Biologie, CHU Nantes, Nantes, France Cytogenetique Hematologique, Institut de Biologie, CHU Nantes, Nantes, France Laboratoire de Cytogenetique, CHU Lille, Lille, France Unite d hematologie Clinique, CHU Dijon, Dijon, France Service d Hematologie biologique, CHU Dijon, Dijon, France Laboratoire de Cytogenetique, CHU Dijon, Dijon, France Laboratoire d Hematologie, CHU Bordeaux, Bordeaux, France Laboratoire de Cytogenetique Hopital Necker, Assistance Publique Hopitaux de Paris, Paris, France Laboratoire d Hematologie Moleculaire et Cytogenetique, Institut Paoli Calmette, Marseille, Marseille, France Laboratoire d Hematologie, Hopital Purpan ,Toulouse, Toulouse, France Laboratoire de Genetique des Hemopathies, Hopital Purpan, Toulouse, Toulouse, France Laboratoire d Hematologie et de Cytogenetique, CH Reims, Reims, France Laboratoire d Hematologie, Etablissement de Transfusion Sanguine de Franche Comte, Besancon, France Service d Hematologie, Centre Hospitalier Alger, Alger, Algeria Hematologie Biologique, Hopital Robert Debre, Assistance Publique Hopitaux de Paris, Paris, France Immunologie Biologique, Hopital Robert Debre, Assistance Publique Hopitaux de Paris, Paris, France Unite INSERM 301, IGM, Hopital Saint Louis Paris, Paris, France Unite INSERM 524, Institut de Recherche sur le Cancer de Lille, Lille, France; Service des Maladies du Sang, CHU Lille, Lille, France Laboratoire d'Hematologie A, CHU Lille, Lille, France; Unite INSERM 524, Institut de Recherche sur le Cancer de Lille, Lille, France * Corresponding author; email: cpreudhomme{at}chru-lille.fr. Mutations of the AML1 gene are frequent molecular abnormalities in M0 AML, a rare type of AML. In this retrospective multicenter study, morphological, immunophenotypical, cytogenetic and molecular features of 59 de novo M0 AML cases were analysed and correlated to AML1 mutations. Point mutations of AML1 gene were observed in 16 cases (27%). They were correlated with higher WBC count (p=0.001), greater marrow blast involvement (p=0.03), higher incidence of Ig H/TCR gene rearrangement (p<0.0001) and with a border line significance lower incidence of complex karyotypes. In the 59 patients FLT3 mutations were the only significant prognostic factor associated with short survival. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. P.G. Silva, I. Almeida, B. Morolli, G. Brouwer-Mandema, H. Wessels, R. Vossen, H. Vrieling, E. W.A. Marijt, P. J.M. Valk, H. C. Kluin-Nelemans, et al. Genome wide molecular analysis of minimally differentiated acute myeloid leukemia Haematologica, November 1, 2009; 94(11): 1546 - 1554. [Abstract] [Full Text] [PDF] L. Roudaia, M. D. Cheney, E. Manuylova, W. Chen, M. Morrow, S. Park, C.-T. Lee, P. Kaur, O. Williams, J. H. Bushweller, et al. CBF{beta} is critical for AML1-ETO and TEL-AML1 activity Blood, March 26, 2009; 113(13): 3070 - 3079. [Abstract] [Full Text] [PDF] L. Terriou, R. Ben Abdelali, C. Roumier, L. Lhermitte, J. de Vos, P. Cornillet, O. Nibourel, K. Beldjord, H. Dombret, G. Leverger, et al. C/EBPA methylation is common in T-ALL but not in M0 AML Blood, February 19, 2009; 113(8): 1864 - 1866. [Full Text] [PDF] F. P.G. Silva, A. Lind, G. Brouwer-Mandema, P. J.M. Valk, and M. Giphart-Gassler Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients Haematologica, August 1, 2007; 92(8): 1123 - 1126. [Abstract] [Full Text] [PDF] D. Barbaric, T. A. Alonzo, R. B. Gerbing, S. Meshinchi, N. A. Heerema, D. R. Barnard, B. J. Lange, W. G. Woods, R. J. Arceci, and F. O. Smith Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961 Blood, March 15, 2007; 109(6): 2314 - 2321. [Abstract] [Full Text] [PDF] U. Bacher, T. Haferlach, C. Schoch, W. Kern, and S. Schnittger Implications of NRAS mutations in AML: a study of 2502 patients Blood, May 15, 2006; 107(10): 3847 - 3853. [Abstract] [Full Text] [PDF] E. J. Jabbour, E. Estey, and H. M. Kantarjian Adult Acute Myeloid Leukemia Mayo Clin. Proc., February 1, 2006; 81(2): 247 - 260. [Abstract] [Full Text] [PDF] S. Schnittger, C. Schoch, W. Kern, C. Mecucci, C. Tschulik, M. F. Martelli, T. Haferlach, W. Hiddemann, and B. Falini Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype Blood, December 1, 2005; 106(12): 3733 - 3739. [Abstract] [Full Text] [PDF] J. D. Growney, H. Shigematsu, Z. Li, B. H. Lee, J. Adelsperger, R. Rowan, D. P. Curley, J. L. Kutok, K. Akashi, I. R. Williams, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype Blood, July 15, 2005; 106(2): 494 - 504. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020